Oct 10, 2026 08:00AM
Oct 7, 2026 04:11PM
Oct 7, 2026 04:01PM
Oct 6, 2026 08:00AM
Oct 6, 2026 08:00AM
Oct 5, 2026 08:00AM
Oct 5, 2026 08:00AM vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Sep 15, 2026 04:05PM
Sep 2, 2026 08:00AM
Aug 19, 2026 04:05PM
Aug 6, 2026 08:00AM
Jul 28, 2026 04:05PM
Jul 2, 2026 04:05PM
Jun 30, 2026 07:56AM Rodman & Renshaw Starts vTv Therapeutics (VTVT) at Buy
Jun 2, 2026 04:05PM
May 13, 2026 04:01PM
May 8, 2026 04:15PM
May 7, 2026 08:00AM
Apr 7, 2026 04:15PM
Mar 16, 2026 08:00AM
Mar 12, 2026 06:43AM Evercore ISI Starts vTv Therapeutics (VTVT) at Outperform, 'essentially a single-asset story'
Mar 10, 2026 04:01PM
Feb 13, 2026 08:00AM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM
Dec 18, 2025 04:05PM
Nov 6, 2025 04:15PM vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 9, 2025 08:00AM
Oct 9, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 11, 2025 08:00AM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
May 15, 2025 12:00PM
May 15, 2025 12:00PM
Apr 9, 2025 06:03AM
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM
Mar 17, 2025 08:30AM
Dec 9, 2024 07:33AM CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
Nov 12, 2024 04:05PM
Aug 8, 2024 04:15PM
Jul 26, 2024 04:05PM
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM
Jun 24, 2024 04:05PM
May 28, 2024 08:00AM CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
May 20, 2024 12:00PM

335,386 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All